NEWS

09 Dec 19
Shore Capital appointed as Nomad and Broker to Mpac Group

    Shore Capital is delighted to have been appointed as Nomad and Broker to Mpac Group plc (“Mpac”). Mpac is a global packaging solutions group, delivering ingenious and high-speed packaging solutions to businesses around the world. It has a current market capitalisation

ANNOUNCEMENTS

16 Oct 19
SCGL Director/PDMR Shareholding - October 2019

  Shore Capital was notified today that Elizabeth van Messel, the wife of Michael van Messel, a Senior Executive of the Company, has bought 201,283 ordinary shares of no par value in the Company ("Ordinary Shares") at a price of £1.45 per share (the "Purchase"). Following the Purchase,

ANNOUNCEMENTS

15 Oct 19
SCGL - Result of General Meeting - Cancellation of admission to trading on AIM

  Shore Capital Group Limited (“Shore Capital,” the “Group” or the “Company”) Result of General Meeting - Cancellation of admission to trading on AIM Shore Capital Group Limited, the independent investment group specialising in capital markets, asset mana

NEWS

10 Oct 19
Shore Capital appointed as Nominated Adviser and Joint Broker to Epwin Group Plc

    Shore Capital is delighted to have been appointed as Nominated Adviser and Joint Broker to Epwin Group Plc (“Epwin”). Epwin is a leading manufacturer of low maintenance, sustainable and energy efficient products to the new build, social housing, DIY, retail and trade s

ANNOUNCEMENTS

27 Sep 19
SCGL Director/PDMR Shareholding - September 2019

  Shore Capital was notified yesterday that Elizabeth van Messel, the wife of Michael van Messel, a Senior Executive of the Company, has bought 198,717 ordinary shares of no par value in the Company ("Ordinary Shares") at a price of £1.35 per share (the "Purchase"). Following the Purcha

ANNOUNCEMENTS

26 Sep 19
Proposed cancellation of admission of ordinary shares to trading on AIM and Notice of General Meeting

  Shore Capital, the independent investment group specialising in capital markets, asset management and principal finance, today announces its intention to seek shareholder approval to cancel its admission of ordinary shares to trading on the AIM Market of the London Stock Exchange,

ANNOUNCEMENTS

26 Sep 19
Shore Capital announces its interim results for the six months ended 30 June 2019

  Shore Capital, the independent investment group specialising in capital markets, asset management and principal finance, today announces its interim results for the six months ended 30 June 2019.   Financial highlights   •  Revenue up 12.2% to £24.3 million, (201

NEWS

25 Sep 19
Shore Capital acts as Financial Adviser, Nomad and Joint Broker on Amryt Pharma’s acquisition of Aegerion Pharmaceuticals and its $60m fundraise

  Shore Capital is pleased to have acted as Financial Adviser, Nominated Adviser and Joint Broker on Amryt Pharma’s $153m acquisition of Aegerion Pharmaceuticals, Inc. along with a fundraise of $60m in new equity raised from new and existing investors. The acquisition of Aegerion, the

NEWS

03 Sep 19
Shore Capital appointed as Joint Broker to Greencore

  Shore Capital is delighted to have been appointed as Joint Broker to Greencore Group plc (“Greencore”). Dublin based Greencore is a leading manufacturer of convenience foods in the UK with a market capitalisation of c.£900m. The FTSE 250 company, led by Patrick Coveney, ha

CHAIRMAN’S EDITORIAL

02 Sep 19
To thrive after Brexit, we must turbo-charge forgotten corners of the country

Howard Shore, Founder, Puma Brandenburg Ltd & Shore Capital Group Ltd   All entrepreneurs and investors can quickly get a sense of how well a company is doing from the moment we walk through the door. Since Boris Johnson walked into Downing Street, there has been a palpable change in the

NEWS

28 Aug 19
Shore Capital acts as Financial Adviser, Nominated Adviser and Joint Broker on Amryt Pharma’s acquisition of Aegerion Pharmaceuticals, Inc.

    Shore Capital is pleased to have acted as Financial Adviser, Nominated Adviser and Joint Broker on Amryt Pharma’s acquisition of Aegerion Pharmaceuticals, a US based biopharmaceutical company focused on rare and orphan diseases with operations in the US, Europe and certain co

NEWS

22 Aug 19
Shore Capital acts as Broker and Sole Bookrunner on £1.3m fundraise for LightwaveRF

  Shore Capital is pleased to have acted as Broker and Sole Bookrunner on a fundraise of £1.3m for LightwaveRF, the leading smart homes solutions provider. The fundraise consisted of a firm placing and subscription and a conditional subscription, subject to shareholder approval. Lightwa

1 2